SEOUL, Korea, Aug. 25 /PRNewswire/ -- Dong-A PharmTech Co. Ltd. announced the approval of its oral tablet for erectile dysfunction by the Ministry of Health of the Russian Federation. Dong-A PharmTech’s marketing partner, Valenta Pharmaceuticals, one of Russia’s largest pharmaceutical companies is set to launch Zydena during the 4th quarter of this year.
Zydena (generic name, udenafil) is a new long-acting erectile dysfunction drug that will compete with Viagra and Cialis but is distinguished by its long action and low incidence of unfavorable side effects such as vision disturbances and muscle pain. Zydena is expected to capture a significant share of the ED market in Russia in coming years.
Mr. Dong Hyun Park, president of Dong-A PharmTech stated that, “The approval of Zydena in Russia marks a major milestone as we continue to execute our global development and marketing strategy. We congratulate Valenta Pharmaceuticals for its diligent efforts in assisting us in obtaining a timely approval in Russia and look forward to working with them to aggressively launch Zydena in Russia’s growing ED market.”
Zydena was launched in Korea in December 2005 and has captured 24% of the ED market within 2 years, edging out Cialis (23% market share) for second place behind Viagra.
Zydena is in clinical development in the USA for erectile dysfunction. Development programs for other indications such as benign prostatic hyperplasia and pulmonary hypertension are planned as part of an overall global development strategy.
Zydena has a strong intellectual property position with patents in more than 30 countries.
About Dong-A PharmTech Co., Ltd.
Dong-A PharmTech is a late-stage pharmaceutical company incorporated in Korea, focused on the development and commercialization of udenafil worldwide excluding Korea.
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to FDA review and approval, product development and acceptance, manufacturing, competition, and/or other factors, which are outside the control of the Company.
CONTACT: Mr. Chan Won OH, Director, International Business Development,
Tel: +82 2 920 8220, or Fax: +82 2 925 4026, or ocw@donga.co.kr, or Mr. Won
Geun KIM, Deputy General Manager, Tel: +82 2 560 8008, or Fax: + 82 2 563
6517, or wgkim@donga.co.kr, both for Dong-A PharmTech Co. Ltd.